Drug makers may face limits on anemia drugs

Drug makers Amgen and Johnson & Johnson may be forced to limit the targeted patient population and dosing levels for popular anti-anemia drugs to reduce risks to cancer patients. Safety concerns have slowed the growth of the drugs already after the FDA raised concerns about the drugs. The level of the drugs prescribed has the risk of increasing patients’ risks of heart attacks or strokes.

For the full article.

Lawyer Monthly - Legal Awards Winner
The National Trial Lawyers
Elder Care Matters Alliance
American Association for Justice
Fellow Litigation Counsel of America
Super Lawyers